Want to join the conversation?
Biotechnology company $GILD said that the authorization to market the once-daily single tablet regimen Genvoya for the treatment of HIV-1 infection in adults & adolescents has been granted by the European Commission. This authorization is supported by the 48-week data from two ongoing Phase 3 studies among 1,733 treatment-naive adult patients.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)